Ignite Creation Date:
2024-05-05 @ 4:49 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00329303
Status:
COMPLETED
Last Update Posted:
2019-05-06
First Post:
2006-05-22
Brief Title:
Efficacy of Re-treatment With Cimzia in Subject With Chronic Plaque Psoriasis
Sponsor:
UCB Pharma
Organization:
UCB Pharma
Study Overview
Official Title:
Follow-up of Study C87040 Multicentre Double-blind Study to Describe the Efficacy and Safety of Re-treatment With CDP870 Certolizumab Pegol Subcutaneous at 2 Different Dose Regimens 400 mg Initial Dose at Week 0 With 200 mg Every 2 Weeks Thereafter and 400 mg Every 2 Weeks or Placebo for 12 Weeks in Subjects Suffering From Moderate-to-severe Chronic Plaque Psoriasis Who Are Candidates for Systemic Therapy andor Phototherapy andor Photochemotherapy Having Responded to Treatment in Study C87040 and Having Subsequently Relapsed
Status:
COMPLETED
Status Verified Date:
2019-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The primary objective is to assess differences in PASI scores between Week 12 of Study C87040 NCT00245765 and Week 12 of re-treatment in this study
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| 2005-005525-63 | EUDRACT_NUMBER | None | None |